POSB49 Cost Effectiveness Model of Atezolizumab Plus Bevacizumab in Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) in French Setting
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.322
https://www.valueinhealthjournal.com/article/S1098-3015(21)02117-3/fulltext
Title :
POSB49 Cost Effectiveness Model of Atezolizumab Plus Bevacizumab in Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) in French Setting
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02117-3&doi=10.1016/j.jval.2021.11.322
First page :
Section Title :
Open access? :
No
Section Order :
11093